Literature DB >> 31898270

Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.

Md Khalid Anwer1, Muqtader Mohammad2, Muzaffar Iqbal3,4, Mohd Nazam Ansari5, Essam Ezzeldin3,4, Farhat Fatima2, Saad M Alshahrani2, Mohammed F Aldawsari2, Ahmed Alalaiwe2, Aiman A Alzahrani2, Abdullah M Aldayel2.   

Abstract

The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by emulsion solvent evaporation method and optimized using central composite design (CDD). The optimized RXB-PLGA-NPs (F8) with composition, PLGA (125 mg), PVA (0.5%w/w) and RXB (20 mg) was found optimum with particle size (496 ± 8.5 nm), PDI (0.607), ZP (- 18.41 ± 3.14 mV), %EE (87.9 ± 8.6) and %DL (9.5 ± 1.6). The optimized NPs (F8) was further evaluated in vitro for DSC, FTIR, SEM and in vitro release studies. A comparative pharmacokinetic studies with commercial tablet (XARELTO®) were conducted on fasted and fed state rats. Compared to commercial tablet (XARELTO®), the RXB-PLGA-NPs (F8) exhibited a significant enhancement of bioavailability in both fasted and fed state. In addition, the bioavailability of RXB from NPs (F8) was found unaffected in the presence of food.

Entities:  

Keywords:  Bioavailability; Food effect; Nanoparticles; PLGA; Rivaroxaban

Year:  2020        PMID： 31898270     DOI： 10.1007/s11239-019-02022-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  17 in total

1.  Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.

Authors:  Kazuo Minematsu; Takanori Ikeda; Satoshi Ogawa; Takanari Kitazono; Jyoji Nakagawara; Susumu Miyamoto; Yuji Murakawa; Makiko Takeichi; Yoko Kidani; Yutaka Okayama; Toshiyuki Sunaya; Shoichiro Sato; Satoshi Yamanaka
Journal:  Cerebrovasc Dis       Date:  2019-10-02       Impact factor: 2.762

2.  Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.

Authors:  Sunita Metre; Sumit Mukesh; Sanjaya K Samal; Mahesh Chand; Abhay T Sangamwar
Journal:  Mol Pharm       Date:  2018-01-16       Impact factor: 4.939

3.  β-Cyclodextrin-based inclusion complexes and nanocomposites of rivaroxaban for solubility enhancement.

Authors:  Atul P Sherje; Mrunal Jadhav
Journal:  J Mater Sci Mater Med       Date:  2018-12-06       Impact factor: 3.896

4.  Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases.

Authors:  Dalia M N Abouhussein; Dina Bahaa El Din Mahmoud; Ebtehal Mohammad F
Journal:  J Liposome Res       Date:  2019-03-01       Impact factor: 3.648

5.  Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.

Authors:  Craig I Coleman; William L Baker; Anna-Katharina Meinecke; Daniel Eriksson; Brandon K Martinez; Thomas J Bunz; Mark J Alberts
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2020-07-01

6.  A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.

Authors:  Muzaffar Iqbal; Nasr Y Khalil; Faisal Imam; Md Khalid Anwer
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

7.  Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.

Authors:  Charlene Kalani; Elizabeth Awudi; Thomas Alexander; George Udeani; Salim Surani
Journal:  Hosp Pract (1995)       Date:  2019-11-05

8.  Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state.

Authors:  Yanfei Miao; Jiqin Sun; Guoguang Chen; Ren Lili; Pingkai Ouyang
Journal:  Drug Dev Ind Pharm       Date:  2015-12-13       Impact factor: 3.225

9.  Development and evaluation of PLGA polymer based nanoparticles of quercetin.

Authors:  Md Khalid Anwer; Mohammed A Al-Mansoor; Shahid Jamil; Ramadan Al-Shdefat; Mohammad Nazam Ansari; Faiyaz Shakeel
Journal:  Int J Biol Macromol       Date:  2016-07-02       Impact factor: 6.953

10.  New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.

Authors:  Annachiara Bellin; Patrizia Berto; Sakis Themistoclakis; Aastha Chandak; Pietro Giusti; Giacomo Cavalli; Sumeet Bakshi; Michele Tessarin; Paola Deambrosis; Alessandro Chinellato
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240
View more
  3 in total

1.  Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban.

Authors:  Pranav J Shah; Milan P Patel; Jigar Shah; Anroop B Nair; Sabna Kotta; Bhavin Vyas
Journal:  Drug Deliv Transl Res       Date:  2022-04-25       Impact factor: 4.617

2.  Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach.

Authors:  Mohammed Muqtader Ahmed; Md Khalid Anwer; Farhat Fatima; Mohammed F Aldawsari; Ahmed Alalaiwe; Amer S Alali; Abdulrahman I Alharthi; Mohd Abul Kalam
Journal:  Polymers (Basel)       Date:  2022-06-16       Impact factor: 4.967

3.  Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability.

Authors:  Md Khalid Anwer; Essam A Ali; Muzaffar Iqbal; Mohammed Muqtader Ahmed; Mohammed F Aldawsari; Ahmed Al Saqr; Mohd Nazam Ansari; M Ali Aboudzadeh
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.